CLAIMS

What is claimed is:

1. A method for treating metabolic syndrome in a subject, comprising:

preselecting a subject suffering from metabolic syndrome;

administering to said subject an effective amount of a compound of formula (I), such that said subject is treated for said metabolic syndrome, wherein said compound of formula (I) is:



(I)

wherein R_1 and R_2 are independently H or methyl, and enantiomers and pharmaceutically acceptable salts thereof.

2. A method for treating metabolic syndrome in a subject, comprising:

administering to said subject an effective amount of a compound of formula (I), such that said subject is treated for said metabolic syndrome, wherein said compound of formula (I) is:



(I)

wherein R_1 and R_2 are independently H or methyl, and enantiomers and pharmaceutically acceptable salts thereof.

3. The method of claim 1, wherein R_1 is methyl and R_2 is methyl.

4. The method of claim 1, wherein R_1 is hydrogen and R_2 is methyl.

5. The method of claim 1, wherein R_1 is hydrogen and R_2 is hydrogen.

6. The method of claim 1, wherein said compound is (+)-N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine; (+)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine; (+)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine; (-)-N-{1-[1-(4-chlorophenyl)cyclobutyl-3-methylbutyl}-N-methylamine; (-)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine; (-)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine, or mixtures thereof.

7. The method of claim 2, wherein R_1 is methyl and R_2 is methyl.

8. The method of claim 2, wherein R_1 is hydrogen and R_2 is methyl.

9. The method of claim 2, wherein R_1 is hydrogen and R_2 is hydrogen.

10. The method of claim 2, wherein said compound is (+)-N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine; (+)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine; (+)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine; (-)-N-{1-[1-(4-chlorophenyl)cyclobutyl-3-methylbutyl}-N-methylamine; (-)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine; (-)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine, or mixtures thereof.

11. The method of claim 1, wherein said compound is administered in combination with a second therapeutic agent.

12. The method of claim 2, wherein said compound is administered in combination with a second therapeutic agent.

13. A method for treating metabolic syndrome in a subject, comprising:

preselecting a subject suffering from three or more symptoms of metabolic syndrome;

administering to said subject an effective amount of a compound of formula (I), such that said subject is treated for said metabolic syndrome, wherein said compound of formula (I) is:



(I)

wherein R_1 and R_2 are independently H or methyl, and enantiomers and pharmaceutically acceptable salts thereof.

14. The method of claim 13, wherein said subject is suffering from four or more symptoms of metabolic syndrome.

15. The method of claim 13, wherein said subject is suffering from five or more symptoms of metabolic syndrome.

16. A packaged pharmaceutical composition, comprising an effective amount of a compound of formula (I) for the treatment of metabolic syndrome and directions for using said compound to treat metabolic syndrome, wherein said compound of formula (I) is:



(I)

wherein R_1 and R_2 are independently H or methyl, and enantiomers and pharmaceutically acceptable salts thereof.

17. The method of claim 1, wherein the subject is human.

18. The method of claim 2, wherein the subject is human.

19. The method of claim 13, wherein R_1 and R_2 are each methyl and the compound formula (I) is a hydrochloride salt.

20. The packaged pharmaceutical composition of claim 16 wherein R_1 and R_2 are each methyl and the compound of formula (I) is a hydrochloride salt.

5